• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

The Potential Cardiometabolic Effects of Long-Chain Omega-3 Polyunsaturated Fatty Acids: Recent Updates and Controversies
Adv Nutr. 2023 Apr 7:S2161-8313(23)00283-1. doi: 10.1016/j.advnut.2023.03.014. Online ahead of print.ABSTRACTVarious health-related effects of long-chain (LC) omega-3 polyunsaturated fatty acids (PUFAs), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), have been suggested. LC omega-3 PUFAs reduce triglyceride levels and have anti-inflammatory, immunomodulatory, antiplatelet, and vascular protective effects. Controversially, they might help in restoring glucose homeostasis via the gut microbiota. However, previous studies have not shown the clear benefits of LC omega-3 PUFAs for cardiovascular diseases. REDUCE-IT...
Source: Atherosclerosis - April 9, 2023 Category: Cardiology Authors: Jae Hyun Bae Hyunjung Lim Soo Lim Source Type: research

Efficacy and Safety of Omega-3 Fatty Acids in the Prevention of Cardiovascular Disease: A Systematic Review and Meta-analysis
ConclusionModerate evidence showed that the use of omega-3 fatty acids may reduce the risk of major cardiovascular events, myocardial infarction, and cardiovascular death. Compared to other types of omega-3 fatty acids supplements, we support the use of prescription EPA ethyl ester formulations for the prevention of cardiovascular disease, but the potential risk of atrial fibrillation and bleeding cannot be ignored. It is important to note that omega-3 fatty acids should be applied with caution in patients with previous myocardial infarction, which may increase the risk of stroke. Finally, omega-3 fatty acids are relativel...
Source: Cardiovascular Drugs and Therapy - September 14, 2022 Category: Cardiology Source Type: research

‘Significant interaction’: Omega-3 pills linked to 50% higher risk of atrial fibrillation
EXPERTS recently warned poor dietary habits could be fuelling incidence rates of atrial fibrillation . According to data, cases of the condition - which carries a hidden stroke risk - have grown 72 percent over the past two decades. The findings of a recent study, suggest that taking omega-3 supplements at higher doses could be implicated in the risk of the dangerous heart condition.
Source: Daily Express - Health - April 28, 2022 Category: Consumer Health News Source Type: news

Association Between Omega-3 Fatty Acid Treatment and Atrial Fibrillation in Cardiovascular Outcome Trials: A Systematic Review and Meta-Analysis
ConclusionWhile overall AF event rates were low, n-3 FA treatment is associated with increased risk for AF.
Source: Cardiovascular Drugs and Therapy - August 1, 2021 Category: Cardiology Source Type: research

The REDUCE-IT verdict on eicosapentaenoic acid and cardiovascular outcome challenged with STRENGTH
Key pointsSTRENGTH,1 an industry-sponsored, double-blind, randomized, controlled trial investigated the effects of a carboxylic acid (CA) formulation of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (omega-3 CA) vs. corn oil in 13 078 participants with high cardiovascular (CV) risk, hypertriglyceridaemia, and low levels of high-density lipoprotein cholesterol.Eligible patients were randomized to receive 4 g/day of omega-3 CA or corn oil in addition to standard preventive therapies, including statins (high-intensity in 50%), renin-angiotensin-aldosterone system (RAAS) blockers (in 81%), and antiplatelet agents ...
Source: European Heart Journal - February 1, 2021 Category: Cardiology Source Type: research

Study: Fish Oil Doesn ’ t Seem To Prevent Heart Problems
This study is consistent with earlier trials. The US Food and Drug Administration approved the fish oil-based drug Vascepa for heart attack and stroke prevention in 2019. Nissen hopes the FDA will take a look at these studies and reconsider that decision. “But it’s hard to get something undone once the genie gets out of the bottle,” he said. An editorial in the journal that accompanies the study written by Dr. Gregory Curfman, assistant professor of medicine at Harvard Medical School, also suggested the FDA should require a postmarketing clinical trial of a high-dose of fish oil, such as Vascepa, vs. corn...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 16, 2020 Category: Consumer Health News Authors: CBS Boston Tags: Boston News Health Syndicated CBSN Boston CNN fish oil Source Type: news

Effects of n-3 Fatty Acid Supplements in Elderly Patients after Myocardial Infarction: A Randomized Controlled Trial.
Conclusions: We could not detect reduction in clinical events in our elderly patients with a recent AMI, treated with 1.8 g n-3 PUFAs daily for 2 years. Clinical Trial Registration: OMEMI Study; URL: https://clinicaltrials.gov Unique Identifier: NCT01841944. PMID: 33191772 [PubMed - as supplied by publisher]
Source: Circulation - November 15, 2020 Category: Cardiology Authors: Kalstad AA, Myhre PL, Laake K, Tveit SH, Schmidt EB, Smith P, Nilsen DWT, Tveit A, Fagerland MW, Solheim S, Seljeflot I, Arnesen H, OMEMI investigators Tags: Circulation Source Type: research

Impact of Different Doses of Omega-3 Fatty Acids on Cardiovascular Outcomes: a Pairwise and Network Meta-analysis
AbstractPurpose of ReviewOmega-3 fatty acid (O3FA) supplementation has shown conflicting evidence regarding its benefit in cardiovascular events. We performed a pairwise and network meta-analysis to elucidate the benefit of different doses of O3FA supplementation in cardiovascular prevention.Recent FindingsFourteen studies were identified providing data on 125,763 patients. A prespecified cut-off value of< 1 g per day was set for low-dose (LD) O3FA and>  1 g per day for high-dose (HD) O3FA. The efficacy outcomes of interest were total death, cardiac death, sudden cardiac death, myocardial infarction, stroke, co...
Source: Current Atherosclerosis Reports - July 15, 2020 Category: Cardiology Source Type: research

Icosapent Ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
Authors: Bazarbashi N, Miller M Abstract INTRODUCTION: Icosapent Ethyl (IPE) is a highly purified (>96%) form of eicosapentanoic acid, a marine-derived omega-3 fatty acid known to reduce serum triglyceride levels. Experimental and human studies also support anti-atherosclerotic properties of IPE including antioxidant, anti-inflammatory, endothelial and plaque stabilizing effects. In the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT)l),the addition of 4 grams IPE daily resulted in a 25% reduction in cardiovascular events beyond statins and other standard of care therapies. ...
Source: Expert Review of Cardiovascular Therapy - April 2, 2020 Category: Cardiology Tags: Expert Rev Cardiovasc Ther Source Type: research

Efficacy of different doses of omega-3 fatty acids on cardiovascular outcomes: rationale and design of a network meta-analysis.
CONCLUSIONS: The present network meta-analysis results will aid physicians in the decision to prescribe O3FA in patients with or at risk of cardiovascular events. In particular, it will be able to solve controversies emerged from previous randomized clinical trials and meta-analyses regarding the benefit of different doses of O3FA supplementation in the cardiovascular prevention. PMID: 32107906 [PubMed - in process]
Source: Minerva Cardioangiologica - March 1, 2020 Category: Cardiology Tags: Minerva Cardioangiol Source Type: research

AI may help detect atrial fibrillation from a normal rhythm ECG
Preliminary data indicate that a 10 second non-invasive test can identify US patients with intermittent abnormal heart rhythm Related items fromOnMedica ‘Silent’ heart attacks may affect one in 16 people Hypertension raises risk of mitral regurgitation Coronary heart disease remains UK ’s biggest killer Heart disease and stroke deaths plummet in Scotland Omega 3 from seafood linked to healthier ageing
Source: OnMedica Latest News - August 1, 2019 Category: UK Health Source Type: news

Polyunsaturated fatty acids for the primary and secondary prevention of cardiovascular disease.
CONCLUSIONS: This is the most extensive systematic review of RCTs conducted to date to assess effects of increasing PUFA on cardiovascular disease, mortality, lipids or adiposity. Increasing PUFA intake probably slightly reduces risk of coronary heart disease and cardiovascular disease events, may slightly reduce risk of coronary heart disease mortality and stroke (though not ruling out harms), but has little or no effect on all-cause or cardiovascular disease mortality. The mechanism may be via TG reduction. PMID: 30484282 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - November 27, 2018 Category: General Medicine Authors: Abdelhamid AS, Martin N, Bridges C, Brainard JS, Wang X, Brown TJ, Hanson S, Jimoh OF, Ajabnoor SM, Deane KH, Song F, Hooper L Tags: Cochrane Database Syst Rev Source Type: research